SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 5, 2004
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-27914 | | 34-1697351 |
| (State or other jurisdiction of incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification Number) |
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
| ITEM 5. | OTHER EVENTS AND REQUIRED FD DISCLOSURE |
The Registrant issued a press release on May 5, 2004 announcing that it closed its previously announced private placement financing of 5.76 million common shares to institutional investors for aggregate gross proceeds of approximately $18.7 million. A copy of the press release is incorporated herein by reference and filed as Exhibit 99.1 to this Current Report.
| ITEM 7. | FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS |
(c) Exhibits
| 99.1 | Press Release issued by the Registrant on May 5, 2004. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 5, 2004
| | |
Sirna Therapeutics, Inc. |
(Registrant) |
| |
By: | | /s/ Howard W. Robin
|
Name: | | Howard W. Robin |
Title: | | President & Chief Executive Officer |
3
EXHIBIT INDEX
| | |
Exhibit No.
| | Description of Exhibit
|
| |
| 99.1 | | Press Release issued by the Registrant on May 5, 2004. |
4
